Led · Seed · Aug 2026

BioScout builds an AI-powered early warning platform that captures and analyzes airborne crop pathogens before visible field damage occurs. Its automated hardware uses an active wind vane to trap airborne particles onto an internal adhesive tape, which is then positioned beneath a high-resolution robotic microscope for imaging. Proprietary machine learning models analyze the physical morphology of over 40 distinct agricultural threats, including Alternaria and Downy Mildew. The company currently operates a global automated sensor network of about 250 units and plans to scale to 1,000 active deployments by 2029. BioScout intends to expand commercially across Europe and enter the Brazilian soybean market. The company is led by founder and CEO Dr. Lewis Collins and recently raised A$6.75m (US$4.8m) in Seed funding.

Participated · Seed · Aug 2026

Calice develops computational modeling and AI-driven "virtual trials" that simulate plant–environment–management interactions to predict product performance across climates and regions. Its platform combines environmental sequences with client-provided performance data to reduce the number of physical field experiments and shorten product development timelines; the company reports being able to model future years from one or two years of data and to identify more commercial candidates using fewer test sites. Calice works with major agricultural companies including Syngenta, BASF, Corteva, GDM, TMG, Nufarm, Nuseed and Puna.bio across crops such as soybean, corn, wheat, cotton, sugarcane, barley, canola, carinata, potato and sorghum, with discussions underway for horticulture. Founded in 2022, the company has expanded into Brazil and the United States and employs just over 20 professionals, mainly scientists and agronomists. Financially, it completed a roughly $1 million pre-seed and a $2.5 million seed round to fund expansion, and management plans additional fundraising to accelerate growth.

Participated · Seed · Jul 2026

Founded in 2025 and based in Wageningen, Aardaia builds a breeding platform that combines whole-genome sequencing, computational biology and phenotyping to identify and domesticate wild plant species. The company explicitly avoids genetic modification and gene editing, instead accelerating conventional breeding through predictive genomics and high-throughput evaluation. Its first product, the aardaker, is a protein-rich tuber intended to combine root-crop productivity with legume-like nitrogen-fixing properties and to reduce reliance on imported protein crops while requiring no synthetic nitrogen fertilizer. Aardaia expects to screen about 750,000 unique aardaker genotypes this year and plans to scale that to roughly two million with the new funding. The €5 million seed raise will be used to expand the breeding platform and speed development of the aardaker as it continues to create new crop varieties from wild species.

Led · Series A · Apr 2026

Omeza develops and commercializes marine-derived collagen and lipid products for advanced wound care; its lead product, OCM, is an FDA-cleared drug-device wound matrix derived from marine lipids and cold-water fish peptides. OCM is applied to complex wounds and is described as reducing inflammation, disrupting bacterial biofilm, and supporting tissue regeneration as an alternative to traditional skin grafts. The company is already generating revenue through a nationwide commercial partnership while advancing clinical programs aimed at expanding reimbursement across major hard-to-heal wounds. Omeza plans to use the Series A proceeds to accelerate clinical trials, expand commercial capabilities, and build its clinical and real-world evidence base to support broader payer coverage. The company has recently strengthened its governance with new board appointments as it prepares for its next phase of institutional growth.

Participated · Series A · Apr 2026

Founded in 2021, Planetary develops and operates a proprietary full-stack platform for bioprocess design, scale-up and industrial fermentation via its BioBlocks system. The company builds, owns and operates fermentation facilities to produce bio-based proteins, fibres and enzymes and pursues an IP-rich licensing strategy with agro-industrial partners, particularly sugar companies. Planetary has commercial traction through product launches under its B2B brand Libre®, including a nationwide mycoprotein filet launch with ALDI Suisse at price parity. It operates industrial-scale production in Aarberg, Switzerland and is scaling sugar-to-protein upcycling technology globally, targeting ultra-low-cost mycoprotein production below €0.85/kg in collaborations with partners in sucrose-rich regions. Planetary is rolling out additional launches across alternative meat and dairy, meat hybrids, fibre-rich products and protein fortification applications. The company plans to expand its global commercial rollout and technology licensing efforts using the newly raised capital.